31
May 2026
Daraxonrasib significantly extends survival in metastatic pancreatic cancer
At the ASCO annual meeting, Dana-Farber's Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.







